The treatment of primary biliary cirrhosis (PBC) drugs, including accelerated bile excretion, immunomodulation, anti-fibrosis and symptomatic treatment, etc. Orechromycin is the only approved treatment of PBC drugs, for most patients with But there are still some patients do not answer. In addition, the bite class, 6-ethyl chenodeoxycholic acid, budesonide and other treatment for PBC also showed a good prospect, these findings PBC treatment offers a new choice.

The present invention discloses metabolic markers for the diagnosis of coronary atherosclerosis and stable angina, including phosphorylcholine, palmitoyl ethanolamine, phytosphingosine, phosphatidylcholine, ethyl chenodeoxycholic acid, lysophosphatidyl (16: 0), lysophosphatidylcholine (18: 2) and phosphatidylinositol (20: 4/0: 0). The area under the ROC curve (AUC) was greater than 0.7 for patients with stable angina pectoris and coronary atherosclerosis, and had a clinical diagnostic significance. When combined with the number of combinations, AUC was further and the highest sensitivity and specificity were 97.4% and 98.0%, respectively. The optimal sensitivity and specificity were 97.8% and 98.0%, respectively. The metabolic marker provided by the invention can accurately diagnose the distinction between coronary atherosclerosis and stable angina, with high accuracy, high sensitivity and specificity.